Risk of hematological malignancies in the families of patients treated for nodular lymphocyte-predominant Hodgkin lymphoma

Table 1 Patient’s characteristics and outcome

Variable	Total numbers	Percentage
Patients with NLPHL	200	100
No data available	30	15
Malignancy related data available	170	65
Total families* of 170 patients	167	–
Male	130	76.5
Female	40	23.5
Median age	20.9 years	Range (5–64)
Age < 21	86	50.6
Type and frequency of familial malignancies
Family with no malignancy	77	46.1
Families with malignancy	90	53.9
Families with hematological only*	14	8.4
Families with hematological + solid	17	10.2
Families with solid cancers only	59	35.3
Total malignancies in family members	167	–
Total members with malignancy	162	–
Malignancy confirmed	73	43.7
Confirmed among 35 hematological**	28	80
Confirmed among 135 solid**	45	33.3
Malignancy unconfirmed	94	56.3
Unconfirmed among 35 hematological**	7	20
Unconfirmed among 135 solid**	90	66.66
First degree members	51	31.5
Second degree members	85	52.5
Third degree members	26	16
Common familial malignancy by groups*
Hematological malignancies
Non-Hodgkin lymphoma	16	9.6
Hodgkin lymphoma	11	6.6
Leukemia	8	4.8
Solid malignancies
Gastrointestinal	36	21.6
Female genital	13	7.8
Breast	18	10.77
Cancer not otherwise specified	19	11.4
Lung / Head and Neck	17	10.2
Others	27	16.17

Percentages are counted for 170 available patients
*6 patients from 3 families with NHLPH as the only malignancy are counted as 3 families
**Percentages among the hematological and solid malignancies
5 Patient with 2 malignancies each are also adjusted accordingly

ISSN: 1897-4287